Hu Q, Shi Y, Wang H, Bing L, Xu Z
Exp Hematol Oncol. 2025; 14(1):37.
PMID: 40087690
DOI: 10.1186/s40164-025-00627-6.
Demir T, Moloney C, Mahalingam D
Cancers (Basel). 2025; 17(5).
PMID: 40075563
PMC: 11898821.
DOI: 10.3390/cancers17050715.
Saji A, Komel A, Khan M, Niraula S, Naeem B, Ahsan A
Health Sci Rep. 2025; 8(3):e70514.
PMID: 40041773
PMC: 11872690.
DOI: 10.1002/hsr2.70514.
Shi S, Han J, Wu Q, Zhong H, Lei B, Yan Y
J Mol Histol. 2025; 56(2):95.
PMID: 39992461
DOI: 10.1007/s10735-024-10339-6.
Suvieri C, Belladonna M, Volpi C
Cells. 2024; 13(22).
PMID: 39594642
PMC: 11593294.
DOI: 10.3390/cells13221894.
From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.
Gharib E, Robichaud G
Int J Mol Sci. 2024; 25(17).
PMID: 39273409
PMC: 11395697.
DOI: 10.3390/ijms25179463.
The Complex World of Kynurenic Acid: Reflections on Biological Issues and Therapeutic Strategy.
Stone T, Darlington L, Badawy A, Williams R
Int J Mol Sci. 2024; 25(16).
PMID: 39201726
PMC: 11354734.
DOI: 10.3390/ijms25169040.
Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment.
Vitorakis N, Gargalionis A, Papavassiliou K, Adamopoulos C, Papavassiliou A
Cancers (Basel). 2024; 16(16).
PMID: 39199647
PMC: 11352254.
DOI: 10.3390/cancers16162876.
Synergistic Photothermal Tumor Immunotherapy by 1-MT Based on Zeolitic Imidazolate Framework-8 with pH-High Sensitivity.
Su R, Yang Y, Wu H, Liu B, Tian X, Zhou C
Int J Nanomedicine. 2024; 19:8501-8517.
PMID: 39185344
PMC: 11344551.
DOI: 10.2147/IJN.S449820.
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies.
Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C
Exp Hematol Oncol. 2024; 13(1):80.
PMID: 39107856
PMC: 11301948.
DOI: 10.1186/s40164-024-00543-1.
Overcoming Treatment Resistance in Medulloblastoma: Underlying Mechanisms and Potential Strategies.
Slika H, Shahani A, Wahi R, Miller J, Groves M, Tyler B
Cancers (Basel). 2024; 16(12).
PMID: 38927954
PMC: 11202166.
DOI: 10.3390/cancers16122249.
Immune checkpoint inhibitors in colorectal cancer: limitation and challenges.
Yan S, Wang W, Feng Z, Xue J, Liang W, Wu X
Front Immunol. 2024; 15:1403533.
PMID: 38919624
PMC: 11196401.
DOI: 10.3389/fimmu.2024.1403533.
The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.
Uher O, Hadrava Vanova K, Taieb D, Calsina B, Robledo M, Clifton-Bligh R
Endocr Rev. 2024; 45(4):521-552.
PMID: 38377172
PMC: 11244254.
DOI: 10.1210/endrev/bnae005.
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.
Liu H, Tang L, Li Y, Xie W, Zhang L, Tang H
Mol Cancer. 2024; 23(1):20.
PMID: 38254110
PMC: 10802008.
DOI: 10.1186/s12943-023-01928-2.
Inflammation-Associated Cytotoxic Agents in Tumorigenesis.
Arnhold J
Cancers (Basel). 2024; 16(1).
PMID: 38201509
PMC: 10778456.
DOI: 10.3390/cancers16010081.
Microbial metabolites are involved in tumorigenesis and development by regulating immune responses.
Liu J, Tian R, Sun C, Guo Y, Dong L, Li Y
Front Immunol. 2024; 14:1290414.
PMID: 38169949
PMC: 10758836.
DOI: 10.3389/fimmu.2023.1290414.
Tryptophan Metabolism and Gut Microbiota: A Novel Regulatory Axis Integrating the Microbiome, Immunity, and Cancer.
Hou Y, Li J, Ying S
Metabolites. 2023; 13(11).
PMID: 37999261
PMC: 10673612.
DOI: 10.3390/metabo13111166.
Druggable targets for the immunopathy of Alzheimer's disease.
Weaver D
RSC Med Chem. 2023; 14(9):1645-1661.
PMID: 37731705
PMC: 10507808.
DOI: 10.1039/d3md00096f.
Tumor-associated macrophages, dendritic cells, and neutrophils: biological roles, crosstalk, and therapeutic relevance.
Shen M, Du Y, Ye Y
Med Rev (2021). 2023; 1(2):222-243.
PMID: 37724296
PMC: 10388790.
DOI: 10.1515/mr-2021-0014.
Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment.
Rechberger J, Toll S, Vanbilloen W, Daniels D, Khatua S
Diagnostics (Basel). 2023; 13(14).
PMID: 37510143
PMC: 10378552.
DOI: 10.3390/diagnostics13142398.